PHX.AU Pharmx Technologies Ltd
- Market cap
- AUD 46.1M
- P/E
- -
- P/B
- 1.98x
- ROE
- -7.8%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PHX.AU undervalued?
Graham numberThe Graham number of Pharmx Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmx Technologies Ltd fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-7.8%), below 10%.
ROA 1/1
Return on assets (-6.7%) is above the industry median (-7.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-567.8%) is below the industry median (19.3%).
Revenue Growth 1/2
Revenue grew 8.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (2.3%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.0x) is below the industry median (3.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Pharmx Technologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmx Technologies Ltd
Pharmx Technologies Limited, together with its subsidiaries, engages in the technology and software development business in Australia and New Zealand. It offers Pharmx Gateway, an electronic ordering and invoicing solution; Pharmx Marketplace, an e-commerce ordering platform; and Pharmx Analytics, a solution that provides insights for suppliers and buyers. The company was formerly known as Corum Group Limited and changed its name to Pharmx Technologies Limited in October 202…
Full company profilePharmx Technologies Ltd financial statements
Pharmx Technologies Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.8M | 12.4M | 11.2M | 10.6M | 11.9M | 11.9M | 6.02M | 6.49M | 7.32M | 7.62M |
| Gross Profit | 3.35M | 2.44M | 2.44M | 1.37M | 3.38M | 10.5M | 4.81M | 5.25M | 5.96M | -70.0K |
| Operating Income | -1.48M | -146K | 966K | -487K | 1.45M | 340K | -774K | -1.36M | -1.42M | -2.09M |
| EBITDA | 2.30M | 143K | 415K | 314K | 3.00M | 2.54M | 329K | 1.45M | 1.39M | -532K |
| Net Income | -5.88M | 251K | -4.21M | 176K | 1.09M | 252K | -1.05M | -1.77M | -264K | -1.83M |
| EPS | -0.02 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 19.8M | 19.7M | 15.0M | 19.2M | 31.3M | 30.8M | 36.5M | 29.9M | 18.8M | 27.3M |
| Total Liabilities | 5.78M | 5.50M | 5.48M | 5.98M | 8.42M | 7.57M | 14.3M | 13.9M | 2.90M | 3.99M |
| Shareholders' Equity | 14.0M | 14.2M | 9.56M | 13.2M | 22.9M | 23.2M | 22.2M | 16.0M | 15.9M | 23.3M |
| Cash & Short-term Investments | 8.10M | 4.97M | 2.33M | 2.32M | 6.48M | 5.76M | 12.8M | 13.1M | 4.17M | 2.57M |
| Total Debt | - | - | - | 733K | 321K | 326K | 32.0K | 240K | 894K | 540K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 249K | 332K | 1.35M | 369K | 3.16M | 3.28M | 10.9M | 3.21M | -8.13M | 825K |
| Capital Expenditure | 692K | 277K | 265K | 156K | 300K | 96.0K | 85.0K | 16.0K | 28.0K | 20.0K |
| Free Cash Flow | -443K | 55.0K | 1.08M | 213K | 2.86M | 3.19M | 10.9M | 3.19M | -8.16M | 805K |
| Ratios | ||||||||||
| ROE | -42.1% | 1.8% | -44.0% | 1.3% | 4.8% | 1.1% | -4.7% | -11.1% | -1.7% | -7.8% |
| ROA | -29.7% | 1.3% | -28.0% | 0.9% | 3.5% | 0.8% | -2.9% | -5.9% | -1.4% | -6.7% |
| Net Profit Margin | -39.8% | 2.0% | -37.4% | 1.7% | 9.2% | 2.1% | -17.5% | -27.3% | -3.6% | -24.0% |
| Debt to Equity | - | - | - | 0.06x | 0.01x | 0.01x | 0.00x | 0.02x | 0.06x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmx Technologies Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 28, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | AUD 4.49M | 0.01 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | AUD 896K | 0.00 | 82.1% |
| 2020 | AUD 896K | 0.00 | 509.1% |
| 2019 | AUD 896K | 0.00 | - |
| 2018 | AUD 896K | 0.00 | 357.0% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Oct 31, 2005.
Who owns Pharmx Technologies Ltd
- Insiders 55.16%
- Institutions 0.96%
- Public & others 43.88%
- Shares outstanding 669M
- Free float 314M
Pharmx Technologies Ltd company profile
- Company name
- Pharmx Technologies Ltd
- Ticker
- PHX.AU
- ISIN
- AU000000COO1
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Software
- Fiscal year end
- June
- Address
- 1 Castlereagh Street, Sydney, NSW, Australia, 2000
- Phone
- 61 1 3007 24579
- Website
- pharmx.com.au
About Pharmx Technologies Ltd
Pharmx Technologies Limited, together with its subsidiaries, engages in the technology and software development business in Australia and New Zealand. It offers Pharmx Gateway, an electronic ordering and invoicing solution; Pharmx Marketplace, an e-commerce ordering platform; and Pharmx Analytics, a solution that provides insights for suppliers and buyers. The company was formerly known as Corum Group Limited and changed its name to Pharmx Technologies Limited in October 2023. Pharmx Technologies Limited was incorporated in 1950 and is based in Sydney, Australia.
Pharmx Technologies Ltd management
5- Ms. Zoe HillierChief Financial Officer
- Mr. Alistair OrchardCTO
- Mr. Vaughan RyanChief Revenue Officer
- Mr. Taufiq KhanChief Product Officer
- Mr. Christopher FernandesCompany Secretary